^
Association details:
Biomarker:BRAF V600E
Cancer:Thyroid Gland Medullary Carcinoma
Drug:CI-1040 (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with BRAF or RAS Mutations

Excerpt:
Genotypes of various thyroid cancer cell lines and their sensitivity to inhibition by CI-1040.
DOI:
https://doi.org/10.1210/jc.2007-0097